Evidence map›Paper›PMID 27999761›Full record

ArticleOncoimmunology

Novel immunotherapy for adult T-cell leukemia/lymphoma: Targeting aurora kinase A.

Nicholas Paul Casey, Hiroshi Fujiwara, Toshiki Ochi, Masaki Yasukawa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. The role of Aurora-A in human cancers and future therapeutics.American journal of cancer research · 2020
    Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nicholas Paul CaseyDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime University , Toon, Ehime, Japan.
Hiroshi FujiwaraDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime University , Toon, Ehime, Japan.
Toshiki OchiDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime University , Toon, Ehime, Japan.
Masaki YasukawaDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime University , Toon, Ehime, Japan.
Ehime University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult T-cell leukemia/lymphoma is caused by infection with HTLV-1, following a long latent period. Immunotherapy targeting Aurora kinase A, a tumor-associated antigen over-expressed in adult T-cell leukemia/lymphoma, holds great therapeutic potential. We review the evidence in favor of a therapeutic strategy combining vaccination and TCR-gene transfer against this target.

Indexed as

Adult T-cell leukemia/lymphomaaurora kinase Aengineered T cellimmunotherapyT-cell receptor gene

Identifiers

PMID27999761
PMCPMC5139639
OpenAlexW2529173080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.